Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Conformis, Inc. stock logo
CFMS
Conformis
$2.26
$2.25
$1.05
$7.25
$17.80M1.3999,585 shs7,000 shs
Leafly Holdings, Inc. stock logo
LFLY
Leafly
$2.12
-0.5%
$2.89
$1.96
$16.00
$4.88M1.0643,254 shs7,740 shs
CareCloud, Inc. stock logo
MTBC
CareCloud
$3.10
$2.50
$6.75
$47.64M0.8563,000 shs66,900 shs
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
$1.30
+2.4%
$1.30
$0.25
$1.40
$70.12M1.32515,333 shs862,700 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Conformis, Inc. stock logo
CFMS
Conformis
0.00%0.00%0.00%0.00%+50.67%
Leafly Holdings, Inc. stock logo
LFLY
Leafly
-0.47%+1.92%-29.10%-54.89%-66.64%
CareCloud, Inc. stock logo
MTBC
CareCloud
0.00%0.00%0.00%0.00%0.00%
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
0.00%0.00%0.00%0.00%+253.36%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Conformis, Inc. stock logo
CFMS
Conformis
N/AN/AN/AN/AN/AN/AN/AN/A
Leafly Holdings, Inc. stock logo
LFLY
Leafly
2.5199 of 5 stars
3.35.00.00.03.80.80.0
CareCloud, Inc. stock logo
MTBC
CareCloud
N/AN/AN/AN/AN/AN/AN/AN/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Conformis, Inc. stock logo
CFMS
Conformis
2.00
HoldN/AN/A
Leafly Holdings, Inc. stock logo
LFLY
Leafly
2.50
Moderate Buy$6.00183.02% Upside
CareCloud, Inc. stock logo
MTBC
CareCloud
N/AN/AN/AN/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
2.00
Hold$1.11-14.62% Downside

Current Analyst Ratings

Latest MTBC, LFLY, CFMS, and ZYNE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
Leafly Holdings, Inc. stock logo
LFLY
Leafly
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $6.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Conformis, Inc. stock logo
CFMS
Conformis
$57.06M0.31N/AN/A$4.07 per share0.56
Leafly Holdings, Inc. stock logo
LFLY
Leafly
$42.25M0.12N/AN/A($5.72) per share-0.37
CareCloud, Inc. stock logo
MTBC
CareCloud
$139.60M0.00N/A2.43$6.58 per share0.00
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/AN/AN/AN/A$1.01 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Conformis, Inc. stock logo
CFMS
Conformis
-$50.47M-$5.61N/AN/AN/A-72.72%-86.46%-47.65%N/A
Leafly Holdings, Inc. stock logo
LFLY
Leafly
-$9.50M-$4.92N/AN/A-22.48%N/A-39.85%5/9/2024 (Estimated)
CareCloud, Inc. stock logo
MTBC
CareCloud
$2.84M-$0.45N/AN/AN/A3.20%4.54%3.33%N/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
-$35.04M-$0.80N/AN/AN/AN/A-90.03%-72.62%N/A

Latest MTBC, LFLY, CFMS, and ZYNE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Leafly Holdings, Inc. stock logo
LFLY
Leafly
-$1.41-$0.22+$1.19-$0.22$9.49 million$9.75 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Conformis, Inc. stock logo
CFMS
Conformis
N/AN/AN/AN/AN/A
Leafly Holdings, Inc. stock logo
LFLY
Leafly
N/AN/AN/AN/AN/A
CareCloud, Inc. stock logo
MTBC
CareCloud
N/AN/AN/AN/AN/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Conformis, Inc. stock logo
CFMS
Conformis
0.64
5.07
3.30
Leafly Holdings, Inc. stock logo
LFLY
Leafly
N/A
3.74
3.74
CareCloud, Inc. stock logo
MTBC
CareCloud
N/A
1.21
1.19
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/A
3.43
3.43

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Conformis, Inc. stock logo
CFMS
Conformis
10.31%
Leafly Holdings, Inc. stock logo
LFLY
Leafly
15.55%
CareCloud, Inc. stock logo
MTBC
CareCloud
19.68%
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
11.23%

Insider Ownership

CompanyInsider Ownership
Conformis, Inc. stock logo
CFMS
Conformis
3.80%
Leafly Holdings, Inc. stock logo
LFLY
Leafly
11.30%
CareCloud, Inc. stock logo
MTBC
CareCloud
34.90%
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
13.04%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Conformis, Inc. stock logo
CFMS
Conformis
2957.88 million7.58 millionNot Optionable
Leafly Holdings, Inc. stock logo
LFLY
Leafly
1302.30 million2.04 millionOptionable
CareCloud, Inc. stock logo
MTBC
CareCloud
4,10015.22 million9.91 millionNot Optionable
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
2553.94 million46.91 millionOptionable

MTBC, LFLY, CFMS, and ZYNE Headlines

SourceHeadline
Harmony Biosciences Reports Strong Third Quarter 2023 Financial ResultsHarmony Biosciences Reports Strong Third Quarter 2023 Financial Results
finance.yahoo.com - October 31 at 7:57 AM
Why Shares of Harmony Bioscience Are Falling on FridayWhy Shares of Harmony Bioscience Are Falling on Friday
fool.com - October 13 at 12:59 PM
New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder TherapiesNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies
markets.businessinsider.com - October 11 at 9:47 AM
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
finance.yahoo.com - October 11 at 9:47 AM
H.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)H.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)
knoxdaily.com - October 10 at 1:59 PM
Analysts: ZYNE stock price target of $1.25 in 12 monthsAnalysts: ZYNE stock price target of $1.25 in 12 months
knoxdaily.com - October 5 at 6:47 PM
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and InstructionsImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
finance.yahoo.com - October 4 at 7:33 PM
Examining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)Examining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)
knoxdaily.com - October 2 at 3:14 PM
20 Countries With Highest Rate of Epilepsy20 Countries With Highest Rate of Epilepsy
finance.yahoo.com - September 29 at 6:24 PM
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
finance.yahoo.com - September 29 at 1:23 PM
Harmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M deal
bizjournals.com - September 27 at 2:42 PM
Zynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the RiseZynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Rise
knoxdaily.com - September 25 at 8:15 PM
Zynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. WainwrightZynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwright
knoxdaily.com - September 20 at 12:12 PM
Negative sentiment towards ZYNE reflected in surge in short interestNegative sentiment towards ZYNE reflected in surge in short interest
knoxdaily.com - September 15 at 8:27 PM
Insider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals IncInsider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Inc
finance.yahoo.com - September 14 at 11:23 PM
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research SymposiumZynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
finance.yahoo.com - September 14 at 6:23 PM
Zynerba Pharmaceuticals Hit With Shareholder Suit in Pa. Over Allegedly Inadequate Proxy StatementZynerba Pharmaceuticals Hit With Shareholder Suit in Pa. Over Allegedly Inadequate Proxy Statement
law.com - September 11 at 4:04 PM
Positive sentiment towards ZYNE reflected in decline in short interestPositive sentiment towards ZYNE reflected in decline in short interest
knoxdaily.com - September 8 at 5:19 AM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ZYNE, KLRSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ZYNE, KLR
bakersfield.com - August 31 at 5:00 PM
HC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)HC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)
msn.com - August 16 at 4:20 AM
Harmony Makes Rare Disease Play with Potential $200M Zynerba BuyoutHarmony Makes Rare Disease Play with Potential $200M Zynerba Buyout
biospace.com - August 15 at 6:19 PM
Zynerba Pharma (NASDAQ: ZYNE) up 300% - The contingents are worth how much?Zynerba Pharma (NASDAQ: ZYNE) up 300% - The contingents are worth how much?
dhakatribune.com - August 15 at 6:19 PM
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?
finance.yahoo.com - August 15 at 6:19 PM
Zynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNEZynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNE
marketwatch.com - August 14 at 9:48 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Conformis logo

Conformis

NASDAQ:CFMS
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, iTotal CR, and iTotal PS, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also offers Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Brazil, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
Leafly logo

Leafly

NASDAQ:LFLY
Leafly Holdings, Inc. owns and operates a platform to provide consumers with cannabis information and connects consumers to cannabis brands and licensed retailers. The company offers subscription-based marketplace listings, digital advertising solutions, and software as a service-based tools to cannabis retailers; and information, reviews, menus, and ordering and delivery options to its audience through its website and mobile applications. Leafly Holdings, Inc. was founded in 2010 and is headquartered in Seattle, Washington.
CareCloud logo

CareCloud

NASDAQ:MTBC
CareCloud, Inc. brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows, and make better business and care decisions. More than 40,000 providers across the United States count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Services and solutions include revenue cycle management (RCM), practice management (PM), electronic health record (EHR), business intelligence, telehealth, and patient experience management (PXM). CareCloud is headquartered in Somerset, NJ.
Zynerba Pharmaceuticals logo

Zynerba Pharmaceuticals

NASDAQ:ZYNE
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.